C reactive protein utilisation, a biomarker for early COVID-19 treatment

BioSymetrics contributed to a peer-reviewed publication in Thorax of Humanigen's Phase 3 trial of lenzilumab for COVID-19 in which BioSymetrics' analysis identified C reactive protein as the highest predictor of outcome when controlling for all other factors.

View the full study here.

Previous

Paper - Using iterative Machine Learning (Contingent-AI) in a clinical setting
Next

Drivers of Mortality in COVID ARDS Depend on Patient Sub-Type